TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33399174

Group type: EXPERIMENTAL
Intervention: CPR‐MCCD
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CPR‐S
Number of subjects: 32

Group type: COMPARATOR
Intervention: CPR‐W
Number of subjects: 32
Study: 34013839

Group type: EXPERIMENTAL
Intervention: L-Citrulline supplementation
Number of subjects: 10
Study: 36249264

Group type: EXPERIMENTAL
Intervention: Baduanjin imagery
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 33741039

Group type: EXPERIMENTAL
Intervention: Albumin supplementation
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Syndecan-1 (SYN-1)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Syndecan-1 (SYN-1) and VE-cadherin
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Syndecan-1 (SYN-1) and Sphingosine-1-phosphate (S1P)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Sphingosine-1-phosphate (S1P)
Number of subjects: 375
Study: 32400728

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Autogenic inhibition muscle energy technique
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Reciprocal inhibition muscle energy technique
Number of subjects: 78
Study: 35165776

Group type: EXPERIMENTAL
Intervention: Unilateral exoskeleton
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exoskeleton
Number of subjects: 0
Study: 32062864

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham TEAS combined with general anesthesia
Number of subjects: 80
Study: 33260196

Group type: EXPERIMENTAL
Intervention: Yoga intervention (daily sessions for one week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no yoga intervention)
Number of subjects: 34
Study: 35393979

Group type: EXPERIMENTAL
Intervention: Chitosan-coated Chamomilla recutita microparticles
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 54
Study: 34019729

Group type: EXPERIMENTAL
Intervention: DGC-CC
Number of subjects: 150

Group type: COMPARATOR
Intervention: DGC
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 35121249

Group type: EXPERIMENTAL
Intervention: PPN-DBS
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CuN-DBS
Number of subjects: 6

Group type: COMPARATOR
Intervention: Off-DBS
Number of subjects: 6
Study: 34262678

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 36294864

Group type: COMPARATOR
Intervention: 0.12% Chlorhexidine (CHX) mouthwash applied twice a day for 7 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: New Bone Bioactive Liquid (BBL) mouthwash applied twice a day for 7 days
Number of subjects: 81
Study: 34880122

Group type: EXPERIMENTAL
Intervention: Text warning labels (WL) on e-liquid vials
Number of subjects: 313

Group type: COMPARATOR
Intervention: No text warning labels (WL) on e-liquid vials
Number of subjects: 313
Study: 35065101

Group type: EXPERIMENTAL
Intervention: Structured individualized education combined with real‐time continuous glucose monitoring (rt‐CGM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Real‐time continuous glucose monitoring (rt‐CGM) alone (control group)
Number of subjects: 47
Study: 33546020

Group type: EXPERIMENTAL
Intervention: Shenfu injection combined with furosemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple furosemide
Number of subjects: 0
Study: 32501109

Group type: EXPERIMENTAL
Intervention: Primary arthrodesis (PA) of the medial 3 TMT joints
Number of subjects: 48

Group type: COMPARATOR
Intervention: Temporary bridge plate (BP) over the first TMT joint and primary arthrodesis of the second and third TMT joints
Number of subjects: 48
Study: 34719869

Group type: EXPERIMENTAL
Intervention: ADEB (standard chemotherapy plus bortezomib)
Number of subjects: 483

Group type: COMPARATOR
Intervention: ADE (standard chemotherapy without bortezomib)
Number of subjects: 483
Study: 33301814

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Combination (COMB)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Overall service use
Number of subjects: 319
Study: 35013762

Group type: EXPERIMENTAL
Intervention: avoidance‐AAT
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: inhibition‐AAT
Number of subjects: 124

Group type: COMPARATOR
Intervention: sham‐avoidance‐AAT
Number of subjects: 124

Group type: COMPARATOR
Intervention: sham‐inhibition‐AAT
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: all training conditions
Number of subjects: 124
Study: 32070444

Group type: EXPERIMENTAL
Intervention: Serum copeptin levels
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Serum hs‐cTnI levels
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mean CPR duration
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Serum glucose, CK‐MB levels, arterial blood gas levels
Number of subjects: 76
Study: 34283838

Group type: EXPERIMENTAL
Intervention: Randomization of the sequence of events in coinfection process
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Randomization of the sequence of events in independent infection dynamics
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Randomization of daily pattern correlations
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mean outbreak size
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Contact randomization at organizational level
Number of subjects: 3
Study: 35788794

Group type: EXPERIMENTAL
Intervention: Nurse Family Partnership program (n=3806)
Number of subjects: 5670

Group type: COMPARATOR
Intervention: Control group (usual care services, n=1864)
Number of subjects: 5670
Study: 33945977

Group type: EXPERIMENTAL
Intervention: Digital otoscope (Cellscope Oto)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Traditional otoscope
Number of subjects: 188
Study: 32067261

Group type: EXPERIMENTAL
Intervention: Brief cognitive-based psychotherapy plus standard case management
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 147
Study: 34983553

Group type: EXPERIMENTAL
Intervention: Self-efficacy-enhancing intervention (SEEI) comprising personalized exercise guidance and self-efficacy education delivered via one face-to-face education session and four telephone consultations, supplemented by written materials.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care using evidence-based guidelines (Control group)
Number of subjects: 150
Study: 32926803

Group type: EXPERIMENTAL
Intervention: Autoadjusting CPAP (4‐20 cm H2O)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP (pressure fixed at 4 cm H2O)
Number of subjects: 120
Study: 32217739

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 99
Study: 36284289

Group type: EXPERIMENTAL
Intervention: Depth of anesthesia set to BIS 55 (group H)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Depth of anesthesia set to BIS 45 (group L)
Number of subjects: 80
Study: 33689150

Group type: EXPERIMENTAL
Intervention: Immediate exercise intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study: 32738208

Group type: EXPERIMENTAL
Intervention: PVI + LVA ablation
Number of subjects: 145

Group type: COMPARATOR
Intervention: PVI only (Control)
Number of subjects: 145
Study: 36115497

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (high dose, ≥9 breaths per session)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (low dose, <9 breaths per session)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo (high dose)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo (low dose)
Number of subjects: 335
Study: 33085510

Group type: EXPERIMENTAL
Intervention: BFF (BreastFeeding Friend) app
Number of subjects: 87
Study: 32542307

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3
Number of subjects: 273

Group type: COMPARATOR
Intervention: 800 IU vitamin D3
Number of subjects: 273
Study: 35347597

Group type: EXPERIMENTAL
Intervention: R-score (radiomics signature)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: R-fibrosis (integrated radiomic and serum variables)
Number of subjects: 332

Group type: COMPARATOR
Intervention: aspartate transaminase-to-platelet ratio (APRI)
Number of subjects: 332

Group type: COMPARATOR
Intervention: fibrosis-4 index (FIB-4)
Number of subjects: 332
Study: 34797419

Group type: EXPERIMENTAL
Intervention: Artificial oocyte activation (AOA)
Number of subjects: 140
Study: 32524985

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with mitral valve repair (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting only (Group 2)
Number of subjects: 60
Study: 34820974

Group type: EXPERIMENTAL
Intervention: Combination of carboxytherapy and narrowband-ultraviolet B (NB-UVB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Narrowband-ultraviolet B (NB-UVB) alone
Number of subjects: 28
Study: 34348654

Group type: EXPERIMENTAL
Intervention: Bifid triple viable capsules (420 mg, 3 times a day for 2 months)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Mesalazine plus somatostatin
Number of subjects: 130
Study: 33908295

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 32320139

Group type: EXPERIMENTAL
Intervention: Acupressure for 10 minutes before venipuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 90
Study: 36281472

Group type: EXPERIMENTAL
Intervention: Brivanib+Cetuximab
Number of subjects: 750

Group type: COMPARATOR
Intervention: Cetuximab+Placebo
Number of subjects: 750
Study: 33855080

Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (fixed dose of 1000 mL crystalloid fluid)
Number of subjects: 71
Study: 34906619

Group type: EXPERIMENTAL
Intervention: Mandibular single-implant overdentures (1-IODs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Experimental removable complete dentures (eRCDs)
Number of subjects: 22
Study: 33980519

Group type: EXPERIMENTAL
Intervention: Usual care plus an intervention delivered by trained community health workers (non‐specialists)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual care (waiting‐list)
Number of subjects: 242
Study: 35277369

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PFME) from 20 weeks gestation until birth
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine antenatal care only (Control Group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PFME)
Number of subjects: 200
Study: 32527501

Group type: EXPERIMENTAL
Intervention: 1 mg kg−1 methylprednisolone in 5 mL of saline
Number of subjects: 162

Group type: COMPARATOR
Intervention: 5 mL of saline (Control Group)
Number of subjects: 162
Study: 35027153

Group type: EXPERIMENTAL
Intervention: Emotion regulation-focused therapy
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Interpersonal-focused therapy
Number of subjects: 147

Group type: COMPARATOR
Intervention: Wait-list (Control)
Number of subjects: 147
Study: 33104519

Group type: EXPERIMENTAL
Intervention: Rg1 (5 mg, an immunostimulant ginsenoside)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study: 32372215

Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg)
Number of subjects: 50
Study: 34309859

Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Control (no BCG vaccination)
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination in high-risk infants
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Control (no BCG vaccination) in high-risk infants
Number of subjects: 1272
Study: 34414949

Group type: EXPERIMENTAL
Intervention: ART-added physiotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 70
Study: 35365305

Group type: EXPERIMENTAL
Intervention: STEP‐KOA (internet‐based exercise training program, phone counseling, physical therapy)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: STEP‐KOA
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control (arthritis education)
Number of subjects: 345
Study: 33678513

Group type: EXPERIMENTAL
Intervention: Edasalonexent 100 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edasalonexent 67 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or off-treatment control
Number of subjects: 0
Study: 32702697

Group type: EXPERIMENTAL
Intervention: Middle calyx entry (group 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lower calyx entry (group 2)
Number of subjects: 70
Study: 35820832

Group type: EXPERIMENTAL
Intervention: Fibromyalgia Self-management Programme (FSMP), consisting of one 2.5-hour weekly session over six weeks.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control arm (details not specified in the abstract).
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: FSMP (intervention)
Number of subjects: 74
Study: 32525416

Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Isotonic saline
Number of subjects: 200
Study: 34172722

Group type: EXPERIMENTAL
Intervention: PD-L1 blockade
Number of subjects: 366
Study: 33222610

Group type: EXPERIMENTAL
Intervention: 50, 100 or 150 L3 Necator americanus larvae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GI symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barnesiella and other taxa
Number of subjects: 0
Study: 34941114

Group type: EXPERIMENTAL
Intervention: Nebulized enriched heparin (2.5 mg/mL 0.9% saline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (nebulized 0.9% saline)
Number of subjects: 50
Study: 34493643

Group type: EXPERIMENTAL
Intervention: Multimodal intervention for 1 week
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 32896292

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg via oral, nasogastric, or intravenous administration once daily for 10 days) plus standard of care (hydroxychloroquine 400 mg twice daily for 10 days)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Standard of care (hydroxychloroquine 400 mg twice daily for 10 days) without macrolides
Number of subjects: 397
Study: 35817323

Group type: COMPARATOR
Intervention: 40 Gy/15 fractions/3 weeks (standard treatment)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 26 Gy/5 fractions/1 week (novel treatment)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 6 Gy/5 fractions/1 week (to the tumour bed, SIB)
Number of subjects: 271

Group type: COMPARATOR
Intervention: 12 Gy/4 fractions/4 days (sequential boost)
Number of subjects: 271
Study: 34606595

Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 20099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20099
Study: 32309986

Group type: EXPERIMENTAL
Intervention: Holistic Yoga Program (HYP)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Wellness Lifestyle Program (WLP)
Number of subjects: 209
Study: 36231152

Group type: EXPERIMENTAL
Intervention: Ashwagandha (ASH) 400 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study: 32109176

Group type: EXPERIMENTAL
Intervention: Implicit problem‐solving (identification condition)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Explicit problem‐solving (reflection condition)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No practice (control condition)
Number of subjects: 45
Study: 35156040

Group type: EXPERIMENTAL
Intervention: Responsive bassinet used until 6 months postpartum
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Therapist‐assisted cognitive behavioral therapy for insomnia
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sleep hygiene booklet
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Responsive bassinet
Number of subjects: 114
Study: 33591621

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 273

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 273
Study: 35525992

Group type: EXPERIMENTAL
Intervention: Supervised exercise rehabilitation with behavioural and motivational support, delivered remotely online, consisting of individual assessment, 12-week, twice-weekly supervised exercise training, and guided lifestyle physical activity.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Best-practice usual care, delivered remotely online, consisting of a single 30-min, one-to-one practitioner appointment, and general advice on safe and effective physical activity.
Number of subjects: 62
Study: 33431279

Group type: EXPERIMENTAL
Intervention: Chiropractic care (10 sessions over 14 weeks) plus enhanced usual care
Number of subjects: 29

Group type: COMPARATOR
Intervention: Enhanced usual care alone
Number of subjects: 29
Study: 33970363

Group type: EXPERIMENTAL
Intervention: Online training program
Number of subjects: 32
Study: 32720779

Group type: EXPERIMENTAL
Intervention: LT (local training)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: GT (global training)
Number of subjects: 108

Group type: COMPARATOR
Intervention: CG (control group)
Number of subjects: 108
Study: 35897114

Group type: EXPERIMENTAL
Intervention: Immediate revascularisation plus optimised medical therapy (OMT)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Optimised medical therapy (OMT) alone
Number of subjects: 320
Study: 34347723

Group type: EXPERIMENTAL
Intervention: EUS-FNA with ROSE
Number of subjects: 65

Group type: COMPARATOR
Intervention: EUS-FNA without ROSE (non-ROSE)
Number of subjects: 65
Study: 32314631

Group type: EXPERIMENTAL
Intervention: Men reporting erectile dysfunction (ED)
Number of subjects: 48910

Group type: EXPERIMENTAL
Intervention: Men who contacted a GP regarding ED
Number of subjects: 48910

Group type: EXPERIMENTAL
Intervention: Age, smoking status, alcohol consumption, BMI, self-rated physical fitness
Number of subjects: 48910

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 48910

Group type: EXPERIMENTAL
Intervention: Physical fitness
Number of subjects: 48910
Study: 34762528

Group type: EXPERIMENTAL
Intervention: Bosentan (125 mg twice a day for 3 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 34194732

Group type: EXPERIMENTAL
Intervention: 2.5% chlorhexidine solution and 0.9% NaCl
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 40
Study: 36332661

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (60mg loading dose and two subsequent 30mg doses at 2 and 5 hours after misoprostol)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (combined with usual-care non-steroidal anti-inflammatory medications +/− opioids)
Number of subjects: 156
Study: 32805205

Group type: EXPERIMENTAL
Intervention: 24 μg lubiprostone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 12 μg lubiprostone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 36180139

Group type: EXPERIMENTAL
Intervention: Multimodal approach (MET, cervical and scapulothoracic stabilization exercises, postural correction training with ergonomic advice)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MET only (control group)
Number of subjects: 40
Study: 33295809

Group type: COMPARATOR
Intervention: Lorazepam (0.05 mg/kg bolus followed by 4-h normal saline infusion)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.02 mg/kg bolus followed by 4-h infusion at 0.02 mg/kg/h)
Number of subjects: 19
Study: 33073935

Group type: COMPARATOR
Intervention: Patients with PsA only (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with FM-PsA (Group II)
Number of subjects: 60
Study: 36361061

Group type: EXPERIMENTAL
Intervention: Vaping prevention messages (n = 295)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Sun safety messages (n = 274)
Number of subjects: 569
Study: 32726499

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg administered in the morning (N-M)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg administered at night (N-N)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate 5 mg administered in the morning (A-M)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate 5 mg administered at night (A-N)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS and Amlodipine besylate (both drugs)
Number of subjects: 120
Study: 34507102

Group type: EXPERIMENTAL
Intervention: CDP-choline (2 g/day for 8 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 44
Study: 36286885

Group type: EXPERIMENTAL
Intervention: Dietressa (6 tablets per day for 24 weeks)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Combined Dietressa group
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Dietressa-1 group
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Dietressa-2 group
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Dietressa
Number of subjects: 493
Study: 33301386

Group type: EXPERIMENTAL
Intervention: Xbox 360 Kinect activity (30 minutes, three times per week for 6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (normal daily routine)
Number of subjects: 36
Study: 35245879

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) in Subthalamic nucleus (STN)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) in internal pallidum (GPi)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) in STN
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) in both STN and GPi
Number of subjects: 21

Group type: COMPARATOR
Intervention: Deep Brain Stimulation (DBS) in STN and GPi
Number of subjects: 21